Human data.
Human models.
Human translation.
WHY WE EXIST
Ochre exists to end the need for liver transplants.
1.5m people globally die of liver disease. For the vast majority of these, the only curative treatment option is a liver transplant. With just over 40k transplants done globally annually, this is a medical lottery. This is what Ochre exists to change.
European Health for All database. Data missing in 2000.
“Liver disease is the third leading cause of premature death.”
UK Health Security Agency, July 2021
HOW WE DO THINGS DIFFERENTLY
Human Discovery Platform
We’ve invested over $20m to build the most comprehensive human liver data sets. By integrating gene perturbation atlases with patient disease atlases, we make causal predictions about new drug targets.
Human Validation Platform
By combining AI with human validation models such as perfused livers, diseased tissue slices and primary cells, we model biological complexity at scale.
RNA Platform
We make our own RNA therapies in house, reducing R&D cycle times from years to weeks. We believe having a strong RNA modality focus improves our chances of clinical success.
What We're Doing (Pipeline)
Mechanism
Indication
Discovery & Validation
Lead Development
Development Candidate Selection
IND Enabling Studies
Clinical
Internal/ Partnerships
Mechanism: Cytoprotection
Indication: Significant Fibrosis
Internal/Partnerships: Internal
Mechanism: Metabolic
Indication: Cirrhosis (F4 MASH)
Internal/Partnerships: Internal
Mechanism: Multiple
Indication: Significant Fibrosis
Internal/Partnerships: Internal
Mechanism: Regeneration
Indication: Cirrhosis
Internal/Partnerships: Partnership
